Current trends in the treatment of polycystic ovary syndrome with desire for children

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 353-360

  Sastre, Margalida E ^a   Prat, Maria O ^a   Checa, Miguel Angel ^a,b   Carreras, Ramon C ^a  

^a Department of Obstetrics and Gynaecology ^*  (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Clomiphene citrate; Letrozole; Lifestyle; Obesity; Polycystic ovarian syndrome; Pregnancy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GLITAZONE DERIVATIVE; GONADORELIN DERIVATIVE; GONADOTROPIN; INSULIN SENSITIZING AGENT; LETROZOLE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DYSLIPIDEMIA; ESTRADIOL BLOOD LEVEL; EXERCISE; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GLUCOSE INTOLERANCE; GYNECOLOGIC SURGERY; HUMAN; HYPERANDROGENISM; INFERTILITY THERAPY; INSULIN RESISTANCE; LACTIC ACIDOSIS; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; MULTIPLE CYCLE TREATMENT; MULTIPLE PREGNANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY CYCLE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PATIENT MONITORING; PHYSICAL ACTIVITY; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY RATE; RECOMMENDED DRUG DOSE; REVIEW; SALPINGECTOMY; SPONTANEOUS ABORTION; TERATOGENICITY; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRASOUND;

EID: 77949426897     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol. 1987;1:235-245.
2. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet. 1988;1:870-872.
3. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 1988;297:1024-1026.
4. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673-683.
5. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-1236.
6. Bolumar F, Olsen J, Rebagliato M,Saez-Lloret I, Bisanti L. Body mass index and delayed conception: a European multicenter study on infertility and subfecundity. Am J Epidemiol. 2000;151:1072-1079.
7. Weiss JL, Malone FD, Emig D, et al. Obesity, obstetric complications and cesarean delivery rate - a population-based screening study. Am J Obstetric Gynecol. 2004;190:1091-1097.
8. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
9. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-4245.
10. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786-789.
11. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9:359-372.
12. Mulders AG, Laven JS, Eijkemans MJ, Hughes EG, Fauser BC. Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update. 2003;9:429-449.
13. Froen JF, Arnestad M, Frey K, Vege A, Saugstad OD, Stray-Pedersen B. Risk factors for sudden intrauterine unexplained death: epidemiologic characteristics of singleton cases in Oslo, Norway, 1986-1995. Am J Obstet Gynecol. 2001;184:694-702.
14. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673-683.
15. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1999;84:1617-1622.
16. Balen A. Surgical management of PCOS. Best Pract Res Clin Endocrinol Metab. 2006;20:271-280.
17. Gjönnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand. 1994;73:407-412.
18. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online. 2006;12:569-578.
19. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr. 2005;25:391-406.
20. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab. 2006;31:384-391.
21. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
22. Homburg R. Clomiphene citrate - end of an era? A minireview. Hum Reprod. 2005;20:2043-2051.
23. Dickey RP, Taylor SN, Curole DN, Rye PH, Pyrzak R. Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod. 1996;11:2623-2628.
24. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-566.
25. Messinis IE. Ovulation induction: a mini review. Hum Reprod. 2005;20:2688-2697.
26. Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singletons live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod. 2003;18:2357-2362.
27. Legro RS, Myers E. Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum Reprod. 2004;19(8):1697-1704.
28. Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4068-4074.
29. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 2001;75:310-315.
30. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril. 2002;77:101-106.
31. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951-953.
32. Checa MA, Requena A, Salvador C, et al; Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update. 2005;11(4):375-390.
33. Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol. 2008;199(6):596-609.
34. Armstrong VL, Wiggam MI, Ennis CN, et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/ cyproterone acetate. QJ Med. 2001;94:31-37.
35. Holte J, Bergh T, Berne Ch, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:2586-2593.
36. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003;79:927-937.
37. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-169.
38. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77:1095-1105.
39. Meirow D, Yossepowitch O, Rosler A, Brzezinski A, Schenker JG, Laufer Nand Raz I. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod. 1995;10:1951-1956.
40. Acien P, Querada F, Matallin P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999;72:32-40.
41. Van Dam EW, Roelfsema F, Veldhuis JD, et al. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. Am J Physiol Endocrinol Metab. 2002;282:E865-E872.
42. Wahrenberg H, Ek I, Reynisdottir S, Carlstrom K, Bergqvist A, Arner P. Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84:2182-2187.
43. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:812-819.
44. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:2586-2593.
45. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries:correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf). 1989;31:757-763.
46. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab. 1989;68:173-179.
47. Hamilton-Fairley D, Kiddy D, Anyaoku V, Koistinen R, Seppala M, Franks S. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf). 1993;39:363-367.
48. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab. 1997;82:556-560.
49. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18:1928-1932.
50. Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Hum Reprod. 2002;17:2230-2236.
51. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951-956.
52. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortonali F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81:114-119.
53. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-522.
54. Brown JB. Pituitary control of ovarian function - concepts derived from gonadotrophin therapy. Aus NZ J Obstet Gynaecol. 1978;18:46-54.
55. Braid DT. A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem. 1987;27:15-23.
56. Remohí J, Bellver J, Domingo J, Bosch E, Pellicer A. Manual práctico de esterilidad y reproducción humana: aspectos prácticos. Capítulo 5; diagnóstico y tratamiento del síndrome de ovarios poliquísticos. 3rd ed. Madrid, Spain: McGraw-Hill/Interamericana; 2008. p. 49-60.
57. Mitwally M, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305-309.
58. Mitwally M, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril. 2002;77:776-780.
59. Filicori M, Cognigni GW, Taraborrelli S, et al. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab. 2001;86:337-343.
60. Christin-Maitre S, Hugues JN. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Human Reprod. 2003;18:1626-1631.
61. Homburg R, Howlewa CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update. 1999;5:493-499.
62. Dolson WC, MoessnerJ, Millar J, et al. A randomized comparison of the methods of the sperm preparation for intrauterine insemination. Fertil Steril. 1998;70:574-575.
63. Carroll N, Palmer JR. A comparison of intrauterine and intracervical insemination with frozen donor sperm: a meta-analysis. Fertil Steril. 2001;75:656-660.
64. Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2006; 86(5 Suppl):S178-S183.
65. Millar RM, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer. 2000;1(Suppl 1):S94-S95.
66. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85:1774-1777.
67. Bhatnagar AS, Häusler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990;37:1021-1027.
68. Noriega-Portella L, Noriega-Hoces L, Delgado A, Rubio J, Gonzales-Castañeda C, Gonzales GF. Effect of letrozole at 2.5 mg or 5.0 mg/day on ovarian stimulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril. 2008;90:1818-1825.
69. Requena A, Herrero J, Landeras J, et al; Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum Reprod Update. 2008;14:571-582.
70. Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85:1761-1765.
71. Heijnem EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13-21.
72. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Human Reprod. 2006;21:1416-1425.
73. Gjönnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril. 1984;41:20-25.
74. Moreno C, Zuzuarregui J, Muñoz E, et al. Insemination artificial. In: Remohí J, Romero JL, Pellicer A, et al (editors). Manual práctico de esterilidad y reproducción humana. Madrid, Spain: McGraw-Hill/Interamericana; 2000. p. 81-95.
75. Tummon IS, Hening I, Radwanska E, et al. Persistent ovarian cysts following administration of human menopausal and chorionic gonadatrophins: an attenuated form of ovarian hyperstimulation syndrome. Fertil Steril. 1998;49:244-248.
76. Rimington MR, Walter SM, Shaw RW. The use of laparoscopy ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum reprod. 1997;12:1443-1447.